|
[1]ATTA HM.Reversibility and heritability of liver fibrosis:implications for research and therapy[J].World J Gastroenterol, 2015, 21 (17) :5138-5148.
|
|
[2]FRIEDMAN SL.Evolving challenges in hepatic fibrosis[J].Nat Rev Gastroenterol Hepatol, 2010, 7 (8) :425-436.
|
|
[3]FRIEDMAN SL, ROLL FJ, BOYLES J, et al.Hepatic lipocytes:the principal collagen-producing cells of normal rat liver[J].Proc Natl Acad Sci U S A, 1985, 82 (24) :8681-8685.
|
|
[4]RIPPE RA, BRENNER DA.From quiescence to activation:Gene regulation in hepatic stellate cells[J].Gastroenterology, 2004, 127 (4) :1260-1262.
|
|
[5]ELPEK GO.Cellular and molecular mechanisms in the pathogenesis of liver fibrosis:an update[J].World J Gastroenterol, 2014, 20 (23) :7260-7276.
|
|
[6]DUARTE S, BABER J, FUJII T, et al.Matrix metalloproteinases in liver injury, repair and fibrosis[J].Matrix Biol, 2015, 44-46:147-156.
|
|
[7]IREDALE JP.Models of liver fibrosis:exploring the dynamic nature of inflammation and repair in a solid organ[J].J Clin Invest, 2007, 117 (3) :539-548.
|
|
[8]CANBAY A, FRIEDMAN S, GORES GJ.Apoptosis:the nexus of liver injury and fibrosis[J].Hepatology, 2004, 39 (2) :273-278.
|
|
[9]BRUNATI AM, PAGANO MA, BINDOLI A, et al.Thiol redox systems and protein kinases in hepatic stellate cell regulatory processes[J].Free Radic Res, 2010, 44 (4) :363-378.
|
|
[10]WATANABE A, HASHMI A, GOMES DA, et al.Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9[J].Hepatology, 2007, 46 (5) :1509-1518.
|
|
[11]SALLOUM S, HOLMES JA, JINDAL R, et al.Exposure to human immunodeficiency virus/hepatitis C virus in hepatic and stellate cell lines reveals cooperative profibrotic transcriptional activation between viruses and cell types[J].Hepatology, 2016, 64 (6) :1951-1968.
|
|
[12]BRYCESON YT, MARCH ME, LJUNGGREN HG, et al.Activation, coactivation, and costimulation of resting human natural killer cells[J].Immunol Rev, 2006, 214:73-91.
|
|
[13]MOROSO V, METSELAAR HJ, MANCHAM S, et al.Liver grafts contain a unique subset of natural killer cells that are transferred into the recipient after liver transplantation[J].Liver Transpl, 2010, 16 (7) :895-908.
|
|
[14]LUO D, VANDERKERKEN K, BOUWENS L, et al.The role of adhesion molecules in the recruitment of hepatic natural killer cells (pit cells) in rat liver[J].Hepatology, 1996, 24 (6) :1475-1480.
|
|
[15]TAKEDA K, CRETNEY E, HAYAKAWA Y, et al.TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver[J].Blood, 2005, 105 (5) :2082-2089.
|
|
[16]SOJKA DK, PLOUGASTEL-DOUGLAS B, YANG L, et al.Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells[J].Elife, 2014, 3:e01659.
|
|
[17]SHARMA R, DAS A.Organ-specific phenotypic and functional features of NK cells in humans[J].Immunol Res, 2014, 58 (1) :125-131.
|
|
[18]PENG H, SUN R, TANG L, et al.CD62L is critical for maturation and accumulation of murine hepatic NK cells in response to viral infection[J].J Immunol, 2013, 190 (8) :4255-4262.
|
|
[19]TOSELLO-TRAMPONT AC, KRUEGER P, NARAYANAN S, et al.NKp46 (+) natural killer cells attenuate metabolism-induced hepatic fibrosis by regulating macrophage activation in mice[J].Hepatology, 2016, 63 (3) :799-812.
|
|
[20]SUBLESKI JJ, WILTROUT RH, WEISS JM.Application of tissuespecific NK and NKT cell activity for tumor immunotherapy[J].J Autoimmun, 2009, 33 (3-4) :275-281.
|
|
[21]SUN C, SUN HY, XIAO WH, et al.Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy[J].Acta Pharmacol Sin, 2015, 36 (10) :1191-1199.
|
|
[22]SUN C, SUN H, ZHANG C, et al.NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma[J].Cell Mol Immunol, 2015, 12 (3) :292-302.
|
|
[23]BJORKSTROM NK, LJUNGGREN HG, SANDBERG JK.CD56 negative NK cells:origin, function, and role in chronic viral disease[J].Trends Immunol, 2010, 31 (11) :401-406.
|
|
[24]LI F, WEI H, WEI H, et al.Blocking the natural killer cell inhibitory receptor NKG2A increases activity of human natural killer cells and clears hepatitis B virus infection in mice[J].Gastroenterology, 2013, 144 (2) :392-401.
|
|
[25]MELHEM A, MUHANNA N, BISHARA A, et al.Anti-fibrotic activity of NK cells in experimental liver injury through killing of activated HSC[J].J Hepatol, 2006, 45 (1) :60-71.
|
|
[26]RADAEVA S, SUN R, JARUGA B, et al.Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners[J].Gastroenterology, 2006, 130 (2) :435-452.
|
|
[27]FASBENDER F, WIDERA A, HENGSTLER JG, et al.Natural killer cells and liver fibrosis[J].Front Immunol, 2016, 7:19.
|
|
[28]ONG S, LIGONS DL, BARIN JG, et al.Natural killer cells limit cardiac inflammation and fibrosis by halting eosinophil infiltration[J].Am J Pathol, 2015, 185 (3) :847-861.
|
|
[29]MITRA A, SATELLI A, YAN J, et al.IL-30 (IL27p28) attenuates liver fibrosis through inducing NKG2D-rae1 interaction between NKT and activated hepatic stellate cells in mice[J].Hepatology, 2014, 60 (6) :2027-2039.
|
|
[30]GLASSNER A, EISENHARDT M, KRAMER B, et al.NK cells from HCV-infected patients effectively induce apoptosis of activated primary human hepatic stellate cells in a TRAIL-, FasL-and NKG2D-dependent manner[J].Lab Invest, 2012, 92 (7) :967-977.
|
|
[31]MUHANNA N, ABU TAIR L, DORON S, et al.Amelioration of hepatic fibrosis by NK cell activation[J].Gut, 2011, 60 (1) :90-98.
|
|
[32]FRIEDMAN SL.Hepatic stellate cells:protean, multifunctional, and enigmatic cells of the liver[J].Physiol Rev, 2008, 88 (1) :125-172.
|
|
[33]MEHAL W, IMAEDA A.Cell death and fibrogenesis[J].Semin Liver Dis, 2010, 30 (3) :226-231.
|
|
[34]FENG X, YAN J, WANG Y, et al.The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells[J].Mol Immunol, 2010, 47 (14) :2388-2396.
|
|
[35]GAO B, RADAEVA S, JEONG WI.Activation of natural killer cells inhibits liver fibrosis:a novel strategy to treat liver fibrosis[J].Expert Rev Gastroenterol Hepatol, 2007, 1 (1) :173-180.
|
|
[36]JEONG WI, PARK O, RADAEVA S, et al.STAT1 inhibits liver fibrosis in mice by inhibiting stellate cell proliferation and stimulating NK cell cytotoxicity[J].Hepatology, 2006, 44 (6) :1441-1451.
|
|
[37]ULLOA L, DOODY J, MASSAGUE J.Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway[J].Nature, 1999, 397 (6721) :710-713.
|
|
[38]VIVIER E, TOMASELLO E, BARATIN M, et al.Functions of natural killer cells[J].Nat Immunol, 2008, 9 (5) :503-510.
|
|
[39]PENG H, WISSE E, TIAN Z.Liver natural killer cells:subsets and roles in liver immunity[J].Cell Mol Immunol, 2016, 13 (3) :328-336.
|
|
[40]LI Q, YAN Z, LI F, et al.Corrigendum:the improving effects on hepatic fibrosis of interferon-γliposomes targeted to hepatic stellate cells[J].Nanotechnology, 2014, 25 (7) :079501.
|
|
[41]TU Z, HAMALAINEN-LAANAYA HK, CRISPE IN, et al.Synergy between TLR3 and IL-18 promotes IFN-gamma dependent TRAILexpression in human liver NK cells[J].Cell Immunol, 2011, 271 (2) :286-291.
|
|
[42]GRESSNER AM, WEISKIRCHEN R, BREITKOPF K, et al.Roles of TGF-beta in hepatic fibrosis[J].Front Biosci, 2002, 7:d793-d807.
|
|
[43]NIETO N.Oxidative-stress and IL-6 mediate the fibrogenic effects of[corrected]Kupffer cells on stellate cells[J].Hepatology, 2006, 44 (6) :1487-1501.
|
|
[44]FRIEDMAN SL, ARTHUR MJ.Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium.Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors[J].J Clin Invest, 1989, 84 (6) :1780-1785.
|
|
[45]ROCKEY DC, MAHER JJ, JARNAGIN WR, et al.Inhibition of rat hepatic lipocyte activation in culture by interferon-gamma[J].Hepatology, 1992, 16 (3) :776-784.
|
|
[46]BARRON L, WYNN TA.Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages[J].Am J Physiol Gastrointest Liver Physiol, 2011, 300 (5) :g723-g728.
|
|
[47]MENTINK-KANE MM, CHEEVER AW, WILSON MS, et al.Accelerated and progressive and lethal liver fibrosis in mice that lack interleukin (IL) -10, IL-12p40, and IL-13Ralpha2[J].Gastroenterology, 2011, 141 (6) :2200-2209.
|
|
[48]GLASSNER A, EISENHARDT M, KOKORDELIS P, et al.Impaired CD4 (+) T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients[J].JHepatol, 2013, 59 (3) :427-433.
|
|
[49]LANGHANS B, ALWAN AW, KRAMER B, et al.Regulatory CD4+T cells modulate the interaction between NK cells and hepatic stellate cells by acting on either cell type[J].J Hepatol, 2015, 62 (2) :398-404.
|
|
[50]JIAO J, OOKA K, FEY H, et al.Interleukin-15 receptor alpha on hepatic stellate cells regulates hepatic fibrogenesis in mice[J].JHepatol, 2016, 65 (2) :344-353.
|
|
[51]NEL I, LUCAR O, PETITDEMANGE C, et al.Accumulation of intrahepatic TNF-alpha-producing NKp44+NK cells correlates with liver fibrosis and viral load in chronic HCV infection[J].Medicine (Baltimore) , 2016, 95 (19) :e3678.
|
|
[52]WAN Z, XIE G, WU Y, et al.Cytokines elevated in patients with HBV-related acute-on-chronic liver failure promote NK cell mediated cytotoxicity through TRAIL[J].Dig Liver Dis, 2016, 48 (5) :528-535.
|
|
[53]DUNN C, BRUNETTO M, REYNOLDS G, et al.Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage[J].J Exp Med, 2007, 204 (3) :667-680.
|
|
[54]MORISHIMA C, PASCHAL DM, WANG CC, et al.Decreased NKcell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing[J].Hepatology, 2006, 43 (3) :573-580.
|
|
[55]INAGAKI Y, NEMOTO T, KUSHIDA M, et al.Interferon alfa down-regulates collagen gene transcription and suppresses experimental hepatic fibrosis in mice[J].Hepatology, 2003, 38 (4) :890-899.
|
|
[56]BECKER PS, SUCK G, NOWAKOWSKA P, et al.Selection and expansion of natural killer cells for NK cell-based immunotherapy[J].Cancer Immunol Immunother, 2016, 65 (4) :477-484.
|
|
[57]GLAVAN TM, PAVELIC J.The exploitation of Toll-like receptor3 signaling in cancer therapy[J].Curr Pharm Des, 2014, 20 (42) :6555-6564.
|
|
[58]RELJIC R.IFN-gamma therapy of tuberculosis and related infections[J].J Interferon Cytokine Res, 2007, 27 (5) :353-364.
|
|
[59]GIRART MV, FUERTES MB, DOMAICA CI, et al.Engagement of TLR3, TLR7, and NKG2D regulate IFN-gamma secretion but not NKG2D-mediated cytotoxicity by human NK cells stimulated with suboptimal doses of IL-12[J].J Immunol, 2007, 179 (6) :3472-3479.
|
|
[60]BRACCI L, PROIETTI E, BELARDELLI F.IFN-alpha and novel strategies of combination therapy for cancer[J].Ann N Y Acad Sci, 2007, 1112:256-268.
|
DownLoad: